Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
2024年7月10日 - 8:30PM
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:
CNTX), a biopharmaceutical company advancing medicines for solid
tumors, today announced that it has entered into an asset purchase
agreement under which the Company has acquired CT-95, formerly
owned by Link Immunotherapeutics, Inc. (“Link”), a mesothelin
(“MSLN”) x CD3 T cell engaging (“TCE”) bispecific antibody with
first-in-class potential that has received Investigational New Drug
(“IND”) clearance from the U.S. Food and Drug Administration. CT-95
is on track for Phase 1 initiation in the first quarter of 2025.
“We are thrilled to add CT-95, formerly known as LNK101, to our
pipeline. The successful acquisition of this MSLN x CD3 bispecific
antibody is consistent with our focus on building a pipeline of TCE
assets to treat solid tumors,” said Martin Lehr, CEO of Context.
“Context identified MSLN as a target of interest due to its high
prevalence in underserved solid cancers, including ovarian, lung,
and pancreatic. Based on the compelling preclinical data generated
to date, we believe that CT-95 has the potential to be both a
first-in-class and best-in-class MSLN-targeting TCE.”
Mr. Lehr continued, “CT-95 is an IND-cleared asset that we plan
to rapidly progress into clinical trials. We intend to fund the
acquisition of CT-95 and its advancement through the dose
escalation portion of a Phase 1 clinical trial with Context’s
existing cash.”
About CT-95MSLN is a membrane protein
overexpressed by many cancers with limited expression in normal
tissues. One challenge in developing MSLN-targeted therapies has
been the presence of a shed MSLN sink found in both blood and the
tumor microenvironment. CT-95 is a fully humanized bispecific TCE
that employs an IgG-scFv architecture with an effector-silenced
IgG1 backbone and has a relatively low affinity but high avidity
for membrane-bound MSLN, minimizing the impact of the shed sink.
CT-95 is being developed as a therapy for advanced cancers
associated with MSLN expression.
About Context Therapeutics®Context Therapeutics
Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing
medicines for solid tumors. The Company is building an innovative
portfolio of clinical-stage T cell engaging bispecific
therapeutics, including CTIM-76, a selective Claudin 6 (CLDN6) x
CD3 bispecific antibody, and CT-95, a potential first-in-class
mesothelin x CD3 bispecific antibody. Context is headquartered in
Philadelphia. For more information, please
visit www.contexttherapeutics.com or follow the Company
on X (formerly Twitter) and LinkedIn.
Forward-looking StatementsThis press release
contains “forward-looking statements” that involve substantial
risks and uncertainties for purposes of the safe harbor provided by
the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, included in
this press release regarding strategy, future operations,
prospects, plans and objectives of management, including words such
as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,”
“intend,” and similar expressions (as well as other words or
expressions referencing future events, conditions, or
circumstances) are forward-looking statements. These include,
without limitation, statements regarding (i) our expectation to
rapidly progress CT-95 into clinical trials, including Phase 1
initiation in the first quarter of 2025, (ii) our expectation to
fund the acquisition of CT-95 and its advancement through the dose
escalation portion of a Phase 1 clinical trial with our existing
cash, (iii) the potential benefits, characteristics, safety and
side effect profile of CT-95, (iv) the ability of CT-95 to have
benefits, characteristics, manufacturability, and a side effect
profile that is differentiated and/or better than third party
product candidates, (v) the likelihood data will support future
development of CT-95, and (vi) the likelihood of obtaining
regulatory approval for CT-95. Forward-looking statements in this
release involve substantial risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by the forward-looking statements, and we therefore cannot
assure you that our plans, intentions, expectations, or strategies
will be attained or achieved. Other factors that may cause actual
results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
our filings with the U.S. Securities and Exchange Commission,
including the section titled “Risk Factors” contained therein.
Except as otherwise required by law, we disclaim any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result
of new information, future events, or circumstances or
otherwise.
Media Contact:Gina Mangiaracina6
Degrees917-797-7904gmangiaracina@6degreespr.com
Investor Relations Contact:Jennifer
Minai-AzaryContext TherapeuticsIR@contexttherapeutics.com
Context Therapeutics (NASDAQ:CNTX)
過去 株価チャート
から 11 2024 まで 12 2024
Context Therapeutics (NASDAQ:CNTX)
過去 株価チャート
から 12 2023 まで 12 2024